(Q40129444)

17 September 2017

title

Anti-Infectious Human Vaccination in Historical Perspective (English)

1 reference

17 September 2017

Enrico D'Amelio

1

1 reference

17 September 2017

Simonetta Salemi

series ordinal

2

1 reference

17 September 2017

Raffaele D'Amelio

series ordinal

3

1 reference

17 September 2017

publication date

25 November 2015

1 reference

International Reviews of Immunology

17 September 2017

published in

1 reference

17 September 2017

volume

35

1 reference

17 September 2017

issue

3

1 reference

17 September 2017

page(s)

260-290

1 reference

Vaccination greatly reduces disease, disability, death and inequity worldwide

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Smallpox vaccines: New formulations and revised strategies for vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Lessons from the eradication of smallpox: an interview with D. A. Henderson

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Novel approaches to identify protective malaria vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines for the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Cortical state and attention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The history of vaccination and current vaccination policies in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Immunization to protect the US Armed Forces: heritage, current practice, and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Public health assessment of potential biological terrorism agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Smallpox vaccines for biodefense: need and feasibility

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Louis Pasteur, from crystals of life to vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Anthrax vaccines: present status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccination in special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Waldemar Haffkine's cholera vaccines and the Ferran-Haffkine priority dispute.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Protecting against plague: towards a next-generation vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccinology: the name, the concept, the adjectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

How does the level of BCG vaccine protection against tuberculosis fall over time?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Non-specific effect of Bacille Calmette-Guérin vaccine on the immune response to routine immunisations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Diagnosis of extrapulmonary tuberculosis using the Xpert(®) MTB/RIF assay

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The use of yellow fever virus modified by in vitro cultivation for human immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Botulism and vaccines for its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Prevalence of markers of exposure to Bordetella pertussis among Italian young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

THE ANTIGENIC POTENCY OF EPIDEMIC INFLUENZA VIRUS FOLLOWING INACTIVATION BY ULTRAVIOLET RADIATION.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Systems biology of vaccination for seasonal influenza in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

New vaccines against influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines in historic evolution and perspective: a narrative of vaccine discoveries

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Japanese encephalitis: the virus and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

ACTIVE IMMUNITY TO POLIOMYELITIS IN CHIMPANZEES FOLLOWING SUBCLINICAL INFECTION

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

History of polio vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

No country is safe without global eradication of poliomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Live, attenuated rubella-virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Molecular analysis of early postvaccine mumps-like disease in Italian military recruits.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines today, vaccines tomorrow: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

RETRACTION: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

An antigen detected in the blood during the incubation period of serum hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines against Lyme disease: What happened and what lessons can we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A long way: history of the prophylactic papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

21 January 2018

History of vaccination

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Global Illness and Deaths Caused by Rotavirus Disease in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines for rotavirus gastroenteritis universally needed for infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Intussusception risk after rotavirus vaccination in U.S. infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Risk of intussusception after monovalent rotavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Rotavirus vaccines--balancing intussusception risks and health benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccination against Herpes Zoster and Postherpetic Neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Immunization against hepatitis A and hepatitis B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Developments in rabies vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Can successful vaccines teach us how to induce efficient protective immune responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Polysaccharide-specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B Cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differ

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The history of pneumococcal conjugate vaccine development: dose selection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Next generation pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines: from empirical development to rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Six revolutions in vaccinology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Generation of influenza A viruses entirely from cloned cDNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Genome‑based vaccine development: A short cut for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Systems vaccinology: learning to compute the behavior of vaccine induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Pathogenesis of dengue: challenges to molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The global distribution and burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Hepatitis C virus vaccines among people who inject drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Long-term efficacy of a hepatitis E vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Broadly neutralizing antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Designing tomorrow's vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Therapeutic antibodies, vaccines and antibodyomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

40 years on: have we finally got a vaccine for Pseudomonas aeruginosa?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Immunization strategies for Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Mechanism of immunopotentiation and safety of aluminum adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccine adjuvants: the dream becomes real

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

MF59 adjuvanted seasonal and pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Is the adjuvant solely to blame?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Influenza virosomes as vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Mechanisms of action of adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Recent advances of vaccine adjuvants for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines in travel health: from risk assessment to priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Can the military contribute to global surveillance and control of infectious diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Healthcare providers as sources of vaccine-preventable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Low vaccination coverage among italian healthcare workers in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Typhoid fever in Fiji: a reversible plague?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Are anti-infectious vaccinations safe and effective in patients with autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

21 January 2018

Vaccines and biologics

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccines for the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

The global value of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Prophylaxis and therapy of plague

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A brief history of the global effort to develop a preventive HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Dengue virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

A randomized, controlled trial of an aerosolized vaccine against measles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Social distancing and the unvaccinated.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2015.1082177

10.3109/08830185.2015.1082177

21 January 2018

Identifiers

DOI

1 reference

17 September 2017

1 reference